 - Prior and concomitant use of Bevacizumab, and all other drugs investigational or licensed that target Vascular Endothelial Growth Factor VEGFVEGF-Receptors, Raf-kinase inhibitors RKI, Methyl Ethyl Ketone MEK or Farnesyl transferase inhibitors 